Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema
In this sham-controlled trial there were no TEAEs that led to discontinuation of treatment with UBX1325 compared with sham. There were trends suggestive of potential efficacy; larger trials are needed to further evaluate these findings. (Funded by UNITY Biotechnology; ClinicalTrials.gov number, NCT04857996.).
Authors
- Lauren Masaki
- Hani Salehi-Had (ORCID: https://orcid.org/0000-0003-2631-7754)
- Robert B. Bhisitkul (ORCID: https://orcid.org/0000-0003-2274-7570)
- Arshad M. Khanani (ORCID: https://orcid.org/0000-0001-8928-5599)
- Craig Mallinckrodt
- Przemysław Sapieha (ORCID: https://orcid.org/0000-0002-9171-2825)
- Raj K. Maturi (ORCID: https://orcid.org/0000-0002-8894-1846)
- J. Dananberg
- Joshua M. Rathmell
- Sharon Klier
- Anirvan Ghosh
Institutions
- University of Nevada, Reno (US)
- University of California, San Francisco (US)
- Hôpital Maisonneuve-Rosemont (CA)
- Unity Biotechnology (United States) (US)
- Retina Associates (US)
- Midwest Eye Institute (US)
- TetraLogic Pharmaceuticals (United States) (US)
- Sierra Eye Associates (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Université de Montréal (CA)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1056/evidoa2400009
- Citations
- 11
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 18.78